PSYENCE
LIVE

Serial Number

90732485

Owner

Psyence Group Inc.

Attorney

Amy J Benjamin

Filing Date

May 25, 2021

Add to watchlist:

No watchlists yet
View on USPTO

PSYENCE Trademark

Serial Number: 90732485

PSYENCE is a trademark filed by Psyence Group Inc. on May 25, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 29 (Meats & Processed Foods), Class 31 (Natural Agricultural Products). The application is currently pending registration.

Owner Contact Info

Psyence Group Inc.

121 RICHMOND STREET WEST
TORONOTO M5H2K1 , CA

Entity Type: 03

Psyence Biomed Corp.

121 Richmond Street West
Toronto, Ontario M5H2K1 , CA

Entity Type: 03

Trademark Details

Filing Date

May 25, 2021

Registration Date

Not Registered

Published for Opposition

March 14, 2023

Goods & Services

Research and development in the fields of neurological conditions and their treatment and psychological conditions and their treatment; basic and clinical research in the fields of plant-based medicines and psychedelics; research and development in the field of holistic medicines, natural medicine, psychedelics and nootropics; research and development of treatments for mental health conditions; pharmaceutical research and development in the field of psilocybin; research and development in the field of psilocybin, holistic medicines, natural medicine, psychedelics and nootropics; research and development of psilocybin-based treatments for mental health conditions; scientific research in the nature of conducting clinical trials for others in the field of medicine and mental health; providing scientific research information in the field of psilocybin, psychoactive products, psychedelics and nootropics

Fresh edible fungi; fresh edible mushrooms; fresh mushrooms; unprocessed mushrooms

Anti-epileptic pharmaceutical preparations; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system namely brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the relief of pain; preparations for the treatment of mental health disorders; pharmaceutical preparations and herbal supplements for enhancing mental health; pharmaceutical preparations, namely cognitive enhancers for the treatment of mental health disorders; herbal supplements, namely cognitive enhancers; dietary supplements for enhancing mental health, and for the treatment of mental health disorders; dietary and nutritional supplements for alleviating symptoms experienced in the palliative care setting, namely, nausea, anorexia, cachexia, severe intractable pain, severe depressed mood, and insomnia; plant-based supplements for aiding general health, well-being and cognitive function

Dried edible fungi; dried edible mushrooms; dried edible mushrooms; edible fungi oils not containing psilocybin or psilocin, fungal extracts for use as ingredients of nutritional supplements; fruit jellies not being confectionary

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 12, 2025 EXRA
SOU EXTENSION 5 GRANTED
Nov 12, 2025 EX5G
SOU TEAS EXTENSION RECEIVED
Nov 8, 2025 EEXT
SOU EXTENSION 5 FILED
Nov 7, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 6, 2025 EXRA
SOU EXTENSION 4 GRANTED
May 5, 2025 EX4G
SOU EXTENSION 4 FILED
May 5, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
May 5, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 6, 2024 EXRA
SOU EXTENSION 3 GRANTED
Dec 6, 2024 EX3G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 6, 2024 AITU
SOU EXTENSION 3 FILED
Nov 11, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 11, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2024 EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2024 EXRA
SOU EXTENSION 2 GRANTED
Oct 30, 2024 EX2G
NOTICE OF REVIVAL - E-MAILED
Sep 9, 2024 NREV
PETITION GRANTED - EXTENSION REQUEST FILED
Sep 9, 2024 PGEX
TEAS RESPONSE TO PETITION DEFICIENCY RECEIVED
Aug 22, 2024 ERTP
INCOMPLETE PETITION NOTICE MAILED
Jul 31, 2024 PINM
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 20, 2024 ASGN
TEAS RESPONSE TO PETITION DEFICIENCY RECEIVED
Jun 7, 2024 ERTP
INCOMPLETE PETITION NOTICE MAILED
May 14, 2024 PINM
ASSIGNED TO PETITION STAFF
May 13, 2024 APET
SOU EXTENSION 2 FILED
May 9, 2024 EXT2
SOU EXTENSION 1 GRANTED
May 9, 2024 EX1G
NOTICE OF REVIVAL - E-MAILED
Feb 13, 2024 NREV
PETITION TO REVIVE-RECEIVED
Feb 12, 2024 PETR
SOU EXTENSION RECEIVED WITH TEAS PETITION
Feb 12, 2024 TPEX
PETITION TO REVIVE-GRANTED
Feb 12, 2024 PETG
TEAS PETITION TO REVIVE RECEIVED
Feb 12, 2024 PROA
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 11, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 11, 2023 ABN6
SOU EXTENSION 1 FILED
Nov 9, 2023 EXT1
ASSIGNED TO EXAMINER
Oct 4, 2023 DOCK
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 9, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 14, 2023 NPUB
PUBLISHED FOR OPPOSITION
Mar 14, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 9, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 8, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 8, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 8, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 10, 2022 GNRN
NON-FINAL ACTION E-MAILED
Oct 10, 2022 GNRT
NON-FINAL ACTION WRITTEN
Oct 10, 2022 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Aug 22, 2022 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Aug 16, 2022 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 1, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 21, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 21, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 21, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 18, 2022 GNRN
NON-FINAL ACTION E-MAILED
Feb 18, 2022 GNRT
NON-FINAL ACTION WRITTEN
Feb 18, 2022 CNRT
ASSIGNED TO EXAMINER
Feb 7, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 19, 2021 NWOS
NEW APPLICATION ENTERED
May 28, 2021 NWAP